| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Maze Therapeutics, Inc. | President, R&D & CMO | Common Stock | 0 | $0 | $47.23 | 02 Feb 2026 | Direct |
| Maze Therapeutics, Inc. | President, R&D & CMO | Stock Option (Right to Buy) | 297,407 | 02 Feb 2026 | Direct | ||
| Maze Therapeutics, Inc. | President, R&D & CMO | Restricted Stock Units | 40,000 | 22 Sep 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| MAZE | Maze Therapeutics, Inc. | 02 Feb 2026 | 6 | -$534,034 | 4 | President, R&D & CMO | 04 Feb 2026, 16:25 |
| MAZE | Maze Therapeutics, Inc. | 07 Jan 2026 | 3 | -$749,173 | 4 | President, R&D & CMO | 09 Jan 2026, 16:51 |
| MAZE | Maze Therapeutics, Inc. | 02 Jan 2026 | 6 | -$145,193 | 4 | President, R&D & CMO | 06 Jan 2026, 16:31 |
| MAZE | Maze Therapeutics, Inc. | 29 Dec 2025 | 4 | -$1,356,455 | 4 | President, R&D & CMO | 31 Dec 2025, 16:22 |
| MAZE | Maze Therapeutics, Inc. | 22 Sep 2025 | 1 | $0 | 4 | President, R&D & CMO | 24 Sep 2025, 16:24 |
| MAZE | Maze Therapeutics, Inc. | 30 Jan 2025 | 0 | $0 | 3 | President, R&D & CMO | 30 Jan 2025, 16:22 |